OPB-111077
Information
- Drug Name
- OPB-111077
- Description
- Entry(CIViC)
CIViC
[No Data.]
Annotation
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04049825 | Active, not recruiting | Phase 1 | A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL | November 22, 2019 | March 2025 |
| NCT01711034 | Completed | Phase 1 | A Phase 1, Open-label, Multiple Dose Escalation Trial to Determine Safety and Tolerability of Once Daily OPB-111077 in Subjects With Advanced Cancer | June 2012 | December 2015 |
| NCT02250170 | Completed | Phase 1 | Safety and Biomarker of OPB-111077 in Subjects With Advanced Solid Tumor | October 23, 2014 | March 8, 2019 |
| NCT03197714 | Completed | Phase 1 | Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia | September 7, 2017 | March 31, 2020 |
| NCT01942083 | Terminated | Phase 1 | A Phase I, Open Label, Non Randomized, Multicenter, Dose Escalation Clinical Study to Investigate Safety and Tolerability of OPB(Otsuka Pharmaceutical Biwa)-111077 in Subjects With Advanced HCC(Hepatocellular Carcinoma) | May 29, 2013 | July 11, 2016 |
| NCT03158324 | Unknown status | Phase 2 | Phase IIa Dose-Expansion and Biomarker Study of OPB-111077 | May 22, 2017 | November 30, 2020 |
- Target (Drug list of Screening Committee of Anticancer Drugs)
- STAT3